Rosacea Study Approval

/in , , /by

Papulopustular rosacea is a highly visible and distressing chronic inflammatory skin disease characterised by intensely inflamed skin and acne-like breakouts across the face – and new therapies are in demand.

Botanix has today announced that we have received ethics approval for our BTX 1702 Phase 1b clinical study for the treatment of papulopustular rosacea, together with an expansion of the study design.

BTX 1702 is a new formulation which leverages our proprietary drug delivery system Permetrex™ with synthetic cannabidiol.

Our BTX 1702 product offers a novel potential treatment for papulopustular rosacea, with a unique mechanism of action, which could target several aspects in the pathogenesis of the disease.

We are very excited to be initiating this clinical study with leading investigators in Australia and New Zealand.

Read today’s ASX release here.

[The person featured in the above image is not an affiliate or actual patient of Botanix Pharmaceuticals Ltd.]

Progress Report for Australia’s First National AMR Strategy

/in , , /by

The Australian Government has published the Final Progress Report for Australia’s First National Antimicrobial Resistance Strategy 2015–2019 detailing its efforts to limit the incidence of antimicrobial resistance (AMR) in Australia.

The report highlights activities implemented between 2017 and 2019 in the human and animal health, food production and the environment.

Looking ahead, the Australian Government last year announced more than $22.5 million over four years in the 2020­–21 Budget to implement an effective strategic framework for addressing AMR.

Botanix supports all efforts by the government and industry to address this pressing global health emergency. We are proud to be doing our part in the development of our BTX 1801 antimicrobial platform program too – most recently, we published world-first human data showing that our synthetic CBD-based ointment/gel formula can effectively eradicate Staphylococcus Aureus.

Download Australian Government’s Progress Report here.

Presentation: ASX Small and Mid-Cap Conference

/in , , /by

Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, presented at the ASX Small and Mid-Cap Conference today.

View the presentation here: